Categories
News | Displaying 1 - 10 of 100 results.
April 20, 2015

Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, announced today that the PicoWay® picosecond laser received U.S. Food and Drug Administration (FDA) clearance for the treatment of pigmented lesions. The PicoWay picosecond laser previously received FDA clearance for the removal of tattoos in November 2014 and was launched in the U.S. late in the fourth quarter 2014. Read More

March 20, 2015

Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, is proud to showcase revolutionary technologies at the American Academy of Dermatology (AAD) 2015 Meeting – March 20-24 in San Francisco. From the fastest clearing picosecond tattoo removal technology to a painless, non-invasive fat destruction system, to the latest in nonsurgical facial rejuvenation, Syneron Candela remains at the forefront of aesthetic technology. Read More

March 17, 2015

Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, today announced the introduction of the Changing Lives Program, a corporate wide initiative that leverages the company's life-changing technologies with life-changing causes. Launching at the annual American Academy of Dermatology (AAD) meeting in San Francisco on March 21, Changing Lives empowers all 7,000 AAD registrants to select the recipients of Syneron Candela's charitable donations. 

Life-Changing Technology Dedicated To Life-Changing Causes  
Donating to the charity of your choice is easy. Pick up the company's door drop, select your charity and leave the card at the Syneron Candela Booth, 1014; the company will make a direct donation to these causes. "We are not only proud of the outcomes generated by our devices for those in need, we are pleased when we can give back to the community, sharing solutions that make a difference," comments Amit Meridor, CEO of Syneron Candela. Read More

February 25, 2015

UltraShape's new consumer campaign on the Times Square billboard!

February 18, 2015

Syneron Medical Ltd. (NASDAQ: ELOS), a global leader in the aesthetic medical device marketplace, launched a national advertising campaign on February 12, 2015 that promises to help achieve a "flatter tummy without the torture." The multi-channel campaign developed by leading Healthcare Advertising agency Abelson Taylor, highlights UltraShape® as a painless and viable alternative to traditional body shaping – especially for stubborn abdominal fat that is resistant to diet and exercise.  Instead of completing sit-ups, the campaign highlights that consumers might drop up to two waist sizes in just three 45-minute sessions, with some visible results seen as early as two weeks.

As the first and only FDA-approved non-invasive body contouring system of its kind, UltraShape offers measurable fat reduction to the abdominal area (an average of loss of 1.3 – 2.5 inches) without the risks associated with other fat reduction procedures. Pulsed focused ultrasound energy is used to precisely and non thermally target subcutaneous fat, while keeping the surrounding tissue, blood vessels, nerves and muscles intact. Read More

January 15, 2015

NewBeauty Magazine awarded UltraShape® the "Best Body-Contouring Treatment" in its annual 2014 Beauty Choice Awards. As a winner in the coveted "Beauty Game Changers" category, UltraShape is recognized for its innovative ultrasound-based treatment that painlessly and permanently destroys fat in the abdominal area where fat is most resistant to diet and exercise.

Featured alongside an elite list of outstanding aesthetic products, NewBeauty notes that UltraShape was chosen by a panel of thousands of readers, editors and beauty industry experts for its ability to deliver real, noticeable and highly customizable results "without surgery or hours spent in the gym." Read More

November 17, 2014

Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today the US Food and Drug Administration (FDA) clearance of the U-Sculpt™ transducer for its UltraShape™ non-invasive fat destruction platform. The FDA also cleared the V3.1 platform for 25% increase in Ultrasound power in the new U-sculpt transducer and the previously cleared larger VDF transducer. This 25% power enhancement is designed to increase the efficacy of treatment and improve both the user experience and patient comfort.

The UltraShape System is a non-invasive body shaping treatment that uses pulsed focused ultrasound energy to precisely target subcutaneous fat, while keeping the surrounding tissue, vasculature, nerves and muscles intact. UltraShape uses a pure mechanical effect to destroy fat cells without inducing thermal damage. Read More
November 03, 2014

Read More

November 03, 2014

Syneron Medical Ltd. (NASDAQ:ELOS), a leading global aesthetic device company, announced today the US Food and Drug Administration (FDA) clearance of the new PicoWay picosecond device. PicoWay is a state-of-the-art dual wavelength device, with 1064nm and 532nm wavelengths, which utilizes the proprietary PicoWay TechnologyTM to generate picosecond pulses for the removal of tattoos. The FDA clearance is for all tattoo colors: red, yellow and orange for the 532nm wavelength; black, brown, green, blue and purple for the 1064nm wavelength. The US launch of PicoWay will begin immediately, following the launch of the product in the international market in October.

PicoWay incorporates picosecond (one trillionth of a second) pulse duration to generate an ultra-short pulse and very high peak power of laser energy on the skin. The high energy ultra-short picosecond laser pulse creates a strong photo-mechanical impact that optimizes fracturing of tattoo ink. The innovative PicoWay Technology is integrated into a proven, reliable Syneron Candela platform which offers high reliability, superior performance and low cost of ownership. Read More

October 08, 2014

Syneron Medical Ltd. (NASDAQ:ELOS), a leading global aesthetic device company, announced today the international launch of the new PicoWay™ picosecond device at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, The Netherlands, October 8-12, 2014. PicoWay is a state-of-the-art dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes proprietary PicoWay technology to generate picosecond pulses for the treatment of pigmented lesions and tattoos, including recalcitrant tattoos. The staged launch of PicoWay begins in the international market during October 2014 and will continue in the United States in the first half of 2015.

PicoWay incorporates the highest peak power and the shortest pulse durations of any aesthetic laser in the market. The combination of these two technological breakthroughs creates the strongest photo-mechanical impact, which enables the most safe and effective fracturing of tattoo ink or pigmentation. The revolutionary PicoWay technology is integrated into a proven, reliable Candela™ platform which ensures superior performance and low cost of ownership.

PicoWay is CE marked and pending U.S. Food and Drug Administration (FDA) clearance. Syneron anticipates that it will receive U.S. FDA clearance for PicoWay by the end of 2014. Read More

News | Displaying 1 - 10 of 100 results.

Learn more / Purchase options

For clinics and physicians: Fill in your details and we will contact you shortly.
Submit